Clinical trial
Anti-Müllerian Hormone in Breast Cancer Clinical Practice
NCT07896772 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anti-Müllerian Hormone in Breast Cancer Clinical Practice
- Lead sponsor
- Masaryk Memorial Cancer Institute
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 20, 2025
- Completion date
- December 31, 2027
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer
Arms
As registered; 2 arms.
-
Breast Cancer Patients
Women aged 20-55 years with breast cancer at different stages of disease and treatment, including newly diagnosed treatment-naive patients, patients who have completed chemotherapy, patients receiving endocrine therapy without prior chemotherapy, and patients undergoing follow-up after treatment.
-
Healthy Controls
Healthy women aged 20-55 years without a history of breast cancer.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Serum Anti-Müllerian Hormone (AMH) Levels
Serum AMH concentrations will be measured in women with breast cancer at different stages of treatment and in healthy female controls. The distribution of AMH levels will be described in both study populations.
Lead sponsor's other trials
Masaryk Memorial Cancer Institute, most recent start first.
+9 more trials See the organization page
Similar trials
Same condition (Breast Neoplasms) and phase, most recent start first.
+3,018 more trials See the condition page